These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Ceftazidime therapy in patients with cystic fibrosis and multiply-drug-resistant pseudomonas. Blumer JL; Stern RC; Klinger JD; Yamashita TS; Meyers CM; Blum A; Reed MD Am J Med; 1985 Aug; 79(2A):37-46. PubMed ID: 3895917 [TBL] [Abstract][Full Text] [Related]
26. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Blumer JL; Saiman L; Konstan MW; Melnick D Chest; 2005 Oct; 128(4):2336-46. PubMed ID: 16236892 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. Rubio TT; Miles MV; Lettieri JT; Kuhn RJ; Echols RM; Church DA Pediatr Infect Dis J; 1997 Jan; 16(1):112-7; discussion 123-6. PubMed ID: 9002120 [TBL] [Abstract][Full Text] [Related]
28. Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Padoan R; Brienza A; Crossignani RM; Lodi G; Giunta A; Assael BM; Granata F; Passarella E; Vallaperta PA; Xerri L J Pediatr; 1983 Aug; 103(2):320-4. PubMed ID: 6348228 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance. Conil JM; Georges B; Lavit M; Seguin T; Tack I; Samii K; Chabanon G; Houin G; Saivin S Int J Clin Pharmacol Ther; 2007 Oct; 45(10):529-38. PubMed ID: 17966838 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion. Burgess DS; Summers KK; Hardin TC Clin Ther; 1999 Nov; 21(11):1882-9. PubMed ID: 10890260 [TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis. Pettit RS; Neu N; Cies JJ; Lapin C; Muhlebach MS; Novak KJ; Nguyen ST; Saiman L; Nicolau DP; Kuti JL J Antimicrob Chemother; 2016 Jan; 71(1):189-95. PubMed ID: 26416780 [TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations. Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050 [TBL] [Abstract][Full Text] [Related]
33. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. Church DA; Kanga JF; Kuhn RJ; Rubio TT; Spohn WA; Stevens JC; Painter BG; Thurberg BE; Haverstock DC; Perroncel RY; Echols RM Pediatr Infect Dis J; 1997 Jan; 16(1):97-105; discussion 123-6. PubMed ID: 9002118 [TBL] [Abstract][Full Text] [Related]
34. Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients. Vic P; Ategbo S; Turck D; Husson MO; Tassin E; Loeuille GA; Deschildre A; Druon D; Elian JC; Arrouet-Lagandre C; Farriaux JP Eur J Pediatr; 1996 Nov; 155(11):948-53. PubMed ID: 8911895 [TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy. Vinks AA; Mouton JW; Touw DJ; Heijerman HG; Danhof M; Bakker W Antimicrob Agents Chemother; 1996 May; 40(5):1091-7. PubMed ID: 8723446 [TBL] [Abstract][Full Text] [Related]
36. Kinetic parameters of amikacin in cystic fibrosis children. Grenier B; Autret E; Marchand S; Thompson R Infection; 1987; 15(4):295-9. PubMed ID: 3117703 [TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics of ceftazidime in critically ill children: impact of cystic fibrosis. Bui S; Facchin A; Ha P; Bouchet S; Leroux S; Nacka F; Fayon M; Jacqz-Aigrain E J Antimicrob Chemother; 2020 Aug; 75(8):2232-2239. PubMed ID: 32457995 [TBL] [Abstract][Full Text] [Related]
38. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis. Strandvik B; Malmborg AS; Alfredson H; Ericsson A J Antimicrob Chemother; 1983 Jul; 12 Suppl A():283-7. PubMed ID: 6352633 [TBL] [Abstract][Full Text] [Related]
39. Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. Baririan N; Chanteux H; Viaene E; Servais H; Tulkens PM J Antimicrob Chemother; 2003 Mar; 51(3):651-8. PubMed ID: 12615867 [TBL] [Abstract][Full Text] [Related]
40. [Pharmacokinetics of ceftazidime in cystic fibrosis]. Saint Raymond A; Genillier P; Lenoir G Presse Med; 1988 Oct; 17(37):1925-7. PubMed ID: 2973587 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]